HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Changing demographics and attitudes towards health will drive the demand for new and effective treatments for enlarged prostate in the maturing male baby boomer population, according to Brian Doyle, Senior Manager for Worldwide Sales and Marketing for Nymox Pharmaceutical Corporation (NASDAQ:NYMX). Enlarged prostate or benign prostatic hyperplasia (BPH) is currently the fourth most commonly diagnosed ailment of men over the age of 50 in the U.S. (Am J Manag Care. 2006;12(4 Suppl):S83-9). In 2000 alone approximately 4.5 million visits were made to physician offices for a primary diagnosis of BPH (Urological Diseases in America Chapter 2, Benign Prostatic Hyperplasia, National Institutes of Health). This number is expected to rise sharply as the men of the baby boomer generation enter their 50s and 60s.
